XML 13 R2.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 80,968 $ 140,418
Marketable securities 270,028 259,715
Interest receivable 594 375
Accounts receivable 7,311 4,673
Prepaid expenses and other current assets 3,727 5,340
Total current assets 362,628 410,521
Property and equipment, net 18,281 78,723
Intangible assets 53,170 54,243
Goodwill 39,283 40,044
Operating lease right-of-use assets 28,190  
Prepaid rent 33,559  
Other non-current assets 4,118 3,364
Non-current restricted cash 3,500 3,500
Total assets 542,729 590,395
Current liabilities:    
Accounts payable and accrued liabilities 30,135 21,457
Accrued compensation and employee benefits 6,168 9,490
Deferred revenues 54,824 47,564
Total current liabilities 91,127 78,511
Deferred revenues, non-current 100,639 108,273
Long-term portion of lease liabilities 13,299 27,689
Deferred income tax 6,572 6,705
Other non-current liabilities 1,911 1,960
Total liabilities 213,548 223,138
Commitments and contingencies
Stockholders' equity:    
Preferred stock
Common stock 1,023 1,022
Additional paid-in capital 934,112 929,632
Accumulated deficit (603,949) (562,696)
Accumulated other comprehensive loss (2,691) (1,440)
Total Sangamo Therapeutics Inc. stockholders' equity 328,495 366,518
Non-controlling interest 686 739
Total stockholders' equity 329,181 367,257
Total liabilities and stockholders' equity $ 542,729 $ 590,395